Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PRECISION 2: Afatinib in Advanced Cancer with EGFR, HER2, or HER3 Mutations
NCT03810872Phase 2Unknown
- Sponsor
- AstraZeneca
- Start
- Jun 2017
- Primary completion
- Dec 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of afatinib in cancer, sponsored by AstraZeneca. Primary endpoints: Response Rate at 6 weeks and Incidence and Intensity of Adverse Events at 4 weeks. Status: unknown.
02
Drugs
afatinib
03
Conditions
cancer
Beyond the preview
Go deeper on NCT03810872.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03810872.